# ELND005 in Patients With Mild to Moderate Alzheimer's Disease

> **NCT00568776** · PHASE2 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 353 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Placebo Control
- **DRUG:** ELND005
- **DRUG:** ELND005
- **DRUG:** ELND005

## Key facts

- **NCT ID:** NCT00568776
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2019-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568776, "ELND005 in Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00568776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*